TY  -  JOUR
AU  -  Giusti, Raffaele
T1  -  My mission is possible: discussing ethical concerns
about genomics and precision medicine
PY  -  2021
Y1  -  2021-06-01
DO  -  10.1701/3620.36024
JO  -  Recenti Progressi in Medicina
JA  -  Recenti Prog Med
VL  -  112
IS  -  6
SP  -  416
EP  -  418
PB  -  Il Pensiero Scientifico Editore
SN  -  2038-1840
Y2  -  2026/04/23
UR  -  http://dx.doi.org/10.1701/3620.36024
N2  -  Summary. Although there is considerable evidence that precision anticancer drugs may be more effective than “one size fits all” approach, doubts persist about their cost, availability, and overall benefit for patients. With increasing frequency, patients with metastatic malignancies are undergoing next-generation sequencing (NGS) procedures to determine if there is a viable mutation that could guide their first or next line of treatment. However, this could be prohibitive for many disadvantaged patients. Furthermore, efficacy studies are often structured around surrogate endpoints of dubious long-term predictive validity. Moreover, it is necessary to add that it is often a therapy with significant toxicities, especially in over-treated patients. There is no doubt that precision medicine represents the near future of medical oncology, however, questions need to be asked, out of the spotlight and much closer to our patients.
ER  -